Sign up to the RCH diabetes newsletter for regular updates about what is happening at the RCH diabetes clinic or any diabetes updates.
Sign up to the RCH diabetes newsletter
Earlier editions of the RCH diabetes newsletter
September 2021: RCH newsletter 2
March 2021:
RCH newsletter 1
Latest updates
April 2021: Tandem T-Slim X2 insulin pump temporary suspension has been lifted by the TGA
Click here for more information
February 2021: Blood glucose record books
Currently we do not have a supply of blood glucose record books to give to families. See below link for an online/printable record book.
BGL record book
From 1 July, 2020 Optisulin is the new name for Lantus insulin
Information on name change from Lantus (insulin glargine) to Optisulin (insulin glargine)
There will be a change over period from 1 January, 2020 until the 30 June, 2020 where Lantus is still available. From 1 July, 2020 Lantus will be de-listed from the PBS and Optisulin will be prescribed by your endocrinologist in its place.
Continuous Glucose Monitoring Initiative: FreeStyle Libre added and eligibility criteria streamlined from 1 March 2020
(Press Release)
Federal Government Subsidy For Continuous Glucose Monitoring (CGM)
On April 1 2017 the Federal Government announced that continuous glucose monitoring (CGM) would be fully subsidised for many children and young adults up to 21 years of age (
Press Release). There is specific criteria for the subsidy to apply (
Criteria), and many of our patients are eligible.
Go to the
diabetes technology page for more information on CGM and starting CGM at RCH
If you would like to apply for a CGM and have a NDSS eligibility form, email diabetes@rch.org.au
Privacy statement for diabetes technology
Important information regarding the Terms and Conditions of your cloud based data.
The RCH takes your private information very seriously. It is important when some technology is agreed as a treatment option, you have read and understood the relevant company’s terms and conditions of use.
Almost all current diabetes technologies such as insulin pumps and continuous glucose monitors rely on cloud based technology to allow both the user, and the treating team to view the data. The ability to review this data, and share it with the treating team is vital to managing diabetes. It is very important that you are aware of how these companies manage your data. When you register to use the uploading or recording facility of the device, the company will ask you to agree to a series of terms and conditions. Within these terms and conditions are privacy statements about how the companies may use the data. For some systems, the RCH is required to agree on behalf of a user who is already registered. This is so we can see the data to provide clinical advice, but this does override the terms agreed to by the user at initial registration.
There is no suggestion that any data is or has been used inappropriately, but we strongly recommend that families are aware of what is being agreed to by accepting terms and conditions.